Cite
APA Citation
Rundquist, S., Sachs, M. C., Eriksson, C., Olén, O., Montgomery, S., Halfvarson, J., & , (2021). drug survival of anti‐TNF agents compared with vedolizumab as a second‐line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers. Alimentary pharmacology & therapeutics, 53(4), 471–483. http://access.bl.uk/ark:/81055/vdc_100120112600.0x00004b